Emerging Horizons in Ovarian Cancer Exploiting Pathways of Susceptibility

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

FDA-Approved Drugs for Ovarian Cancer

FDA-Approved PARP Inhibitors

Cellular DNA Repair Pathways

PARP Trapping

Phase 3 PARP Inhibitor Maintenance Studies

SOLO2/ENGOT-OV21: Olaparib vs Placebo as Maintenance Therapy After Platinum-Based Treatment, Phase 3

ENGOT-OV16/NOVA: Niraparib vs Placebo as Maintenance Therapy After Platinum-Based Treatment, Phase 3

ARIEL3: Rucaparib vs Placebo as Maintenance Therapy After Platinum-Based Treatment, Phase 3

Quality-Associated PFS With Olaparib, SOLO2

Time Without Symptoms of Disease or Toxicity (TWiST)

Mechanisms of Resistance to PARP Inhibitors

Enhancing Anti-Tumor Activity Combining PARPi’s with Other Targeted Therapies

Potential Overlap of DNA Repair and Angiogenic Pathways

PARPi Plus Anti-Angiogenic Therapy Olaparib + Cediranib, Phase 2

PARPi Plus Anti-Angiogenic Therapy Olaparib + Cediranib, Ongoing Studies

PARPi Plus Anti-Angiogenic Therapy Niraparib + Bevacizumab

PARPi Plus Checkpoint Inhibitors Durvalumab + Olaparib or Cediranib, Phase 1

PARPi Plus Checkpoint Inhibitors Niraparib + Pembrolizumab, Ongoing Phase 1/2

PARPi Plus Checkpoint Inhibitors Ongoing Clinical Trials

Other Combination Therapy

PARPi Plus Chemotherapy Veliparib + Carboplatin/Paclitaxel, Ongoing Phase 3

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)